# GNMX (Corgi Genomics & Precision Medicine ETF)

Corgi · Thematic ETFs · data as of Sep 11, 2026

GNMX has not filed its holdings yet, so there is nothing to look through.

## Key facts

- GNMX, total return, since launch: +32.8%, as of Sep 11, 2026.
- GNMX, expense ratio: 0.35% (485BPOS XBRL, Apr 30, 2026).

## GNMX over each window to Sep 11, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | +29.2% | +3.3% | +25.9 pts | +30.0 pts |
| Since launch | +32.8% | +4.4% | +28.4 pts | +30.0 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Biotech and genomics | ETFIQ, editorial |
| Launched | May 6, 2026 | ETFIQ |
| Below its all-time high | −6.5% | ETFIQ |
| Expense ratio | 0.35% | 485BPOS XBRL, Apr 30, 2026 |

## Questions

### Has GNMX beaten the S&P 500?

Over the year to Sep 11, 2026 GNMX returned +32.8% with distributions reinvested, against +4.4% for the S&P 500, so it finished ahead of the index by 28.4 points.

### What does GNMX cost?

The prospectus expense ratio is 0.35% a year.


## Cite this page

ETFIQ, GNMX, data as of Sep 11, 2026. https://etfiq.com/funds/GNMX
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/GNMX  ·  JSON: https://etfiq.com/funds/GNMX.json